Ono Kenichiro, Shirotani Toshiki, Wada Kojiro, Takahara Takashi, Matsushita Yoshitaro, Yuba Koji, Yamana Daigo
Department of Neurosurgery, Japan Self Defense Forces Central Hospital, Tokyo.
No Shinkei Geka. 2005 Feb;33(2):133-40.
Intra-arterial infusion (IA) of fasudil hydrochloride for cerebral vasospasm is performed in many institutions and is associated with few side effects. Nonetheless, as optimum dose and duration of action remain unknown, the present study aimed to clarify these variables. We performed intra-arterial injection of fasudil hydrochloride for eight patients with cerebral vasospasm 7-13 days after subarachnoid hemorrhage. Fasudil hydrochloride was administered via the internal carotid artery without selective microcatheterization, at a concentration and speed of 30 mg/20 ml/10-15 min, using a total dose of 30-60 mg. Cerebral angiography was used to measure change in blood vessel diameter at 19 points, and perfusion CT was used to detect changes in cerebral blood perfusion (CBP), cerebral blood volume (CBV), and mean transit time (MTT) at 12 hemispheres. Investigations were performed before IA, immediately after IA (post IA), and 4.5 to 6 hours later. For central vessels, (A1, M1) mean change in diameter (cm) measured pre IA, post IA, and 4.5-6 hours later was 1.2 +/- 0.68, 1.5 +/- 0.72, and 1.2 +/- 0.7, respectively. For peripheral vessels (peripheral to A1, M1, and the ophthalmic artery) change in diameter (cm) was 0.65 +/- 0.16, 0.97 +/- 0.24, and 0.71 +/- 0.24, respectively. Average CBP (m/100g/min) in the infused hemisphere at pre IA, post IA, and 4.5-6 hours later was 41.6 +/- 3.56, 46.4 +/- 5.82, 41.6 +/- 7.42, respectively. Average CBV (ml/100g) was 2.72 +/- 0.21, 2.73 +/- 0.21, 2.91 +/- 0.42, respectively and average MTT (sec) was 5.16 +/- 0.38, 4.57 +/- 0.70, 5.55 +/- 1.0, respectively. Changes in peripheral vessel diameter and in MTT were statistically significant. Therefore, when performing intra-arterial administration of fasudil hydrochloride, clinicians should be aware that vasodilator effect is less than 6 hours.
许多机构都在进行盐酸法舒地尔动脉内输注(IA)治疗脑血管痉挛,且副作用较少。尽管如此,由于最佳剂量和作用持续时间尚不清楚,本研究旨在阐明这些变量。我们对8例蛛网膜下腔出血后7 - 13天出现脑血管痉挛的患者进行了盐酸法舒地尔动脉内注射。盐酸法舒地尔通过颈内动脉给药,未进行选择性微导管插入,浓度和速度为30 mg/20 ml/10 - 15分钟,总剂量为30 - 60 mg。采用脑血管造影测量19个点的血管直径变化,采用灌注CT检测12个半球的脑血流灌注(CBP)、脑血容量(CBV)和平均通过时间(MTT)变化。在IA前、IA后即刻(IA后)以及4.5至6小时后进行检查。对于中央血管(A1、M1),IA前、IA后以及4.5 - 6小时后测量的平均直径变化(cm)分别为1.2±0.68、1.5±0.72和1.2±0.7。对于外周血管(A1、M1和眼动脉外周),直径变化(cm)分别为0.65±0.16、0.97±0.24和0.71±0.24。IA前、IA后以及4.5 - 6小时后,输注半球的平均CBP(m/100g/min)分别为41.6±3.56、46.4±5.82、41.6±7.42。平均CBV(ml/100g)分别为2.72±0.21、2.73±0.21、2.91±0.42,平均MTT(秒)分别为5.16±0.38、4.57±0.70、5.55±1.0。外周血管直径和MTT的变化具有统计学意义。因此,在进行盐酸法舒地尔动脉内给药时,临床医生应意识到血管舒张作用小于6小时。